OBJECTIVES: Deregulated serum IL-10, IL-12 and their reciprocal balance have been stated in malignancies of adults. In children with cancer the issue has not been investigated so far. DESIGN AND METHODS: To determine the diagnostic and prognostic roles of pre-treatment serum levels of IL-10 (Th2 cytokine), IL-12 (Th1) and their ratios (measured by the IL-10 and IL-12p70 ELISA kits; Endogen) in 91 children with soft tissue sarcomas (STS), Hodgkin's lymphomas (HL) and acute lymphoblastic leukemias (ALL). RESULTS: Median IL-10 and IL-12 levels were significantly higher in cancer patients than in healthy controls. Increased IL-10 indicated presence of general symptoms in HL and high risk group in ALL. Elevated IL-10 and IL-10/IL-12 ratios and decreased IL-12 correlated with poor-risk histology in STS, poor response to therapy, relapse and death from cancer. Multivariate analysis identified IL-10/IL-12 ratio>0.14 and IL-12<40 pg/mL as significant predictors for shorter EFS and OS, respectively. CONCLUSION: Pre-treatment serum levels of IL-10, IL-12 and IL-10/IL-12 balance in children with STS, HL and ALL may be of value as additional prognostic tools to predict the response to therapy and probability of EFS and OS.
OBJECTIVES: Deregulated serum IL-10, IL-12 and their reciprocal balance have been stated in malignancies of adults. In children with cancer the issue has not been investigated so far. DESIGN AND METHODS: To determine the diagnostic and prognostic roles of pre-treatment serum levels of IL-10 (Th2 cytokine), IL-12 (Th1) and their ratios (measured by the IL-10 and IL-12p70 ELISA kits; Endogen) in 91 children with soft tissue sarcomas (STS), Hodgkin's lymphomas (HL) and acute lymphoblastic leukemias (ALL). RESULTS: Median IL-10 and IL-12 levels were significantly higher in cancerpatients than in healthy controls. Increased IL-10 indicated presence of general symptoms in HL and high risk group in ALL. Elevated IL-10 and IL-10/IL-12 ratios and decreased IL-12 correlated with poor-risk histology in STS, poor response to therapy, relapse and death from cancer. Multivariate analysis identified IL-10/IL-12 ratio>0.14 and IL-12<40 pg/mL as significant predictors for shorter EFS and OS, respectively. CONCLUSION: Pre-treatment serum levels of IL-10, IL-12 and IL-10/IL-12 balance in children with STS, HL and ALL may be of value as additional prognostic tools to predict the response to therapy and probability of EFS and OS.
Authors: Christopher A Barker; Samuel K Kim; Sadna Budhu; Konstantina Matsoukas; Anthony F Daniyan; Sandra P D'Angelo Journal: J Immunother Cancer Date: 2018-01-03 Impact factor: 13.751
Authors: Jennifer E Agrusa; Brooks P Scull; Harshal A Abhyankar; Howard Lin; Nmazuo W Ozuah; Rikhia Chakraborty; Olive S Eckstein; Nitya Gulati; Elmoataz Abdel Fattah; Nader K El-Mallawany; Rayne H Rouce; ZoAnn E Dreyer; Julienne Brackett; Judith F Margolin; Joseph Lubega; Terzah M Horton; Catherine M Bollard; M Monica Gramatges; Kala Y Kamdar; Kenneth L McClain; Tsz-Kwong Man; Carl E Allen Journal: Cancers (Basel) Date: 2020-12-02 Impact factor: 6.639
Authors: Poonam Nagpal; Mohamed R Akl; Nehad M Ayoub; Tatsunari Tomiyama; Tasheka Cousins; Betty Tai; Nicole Carroll; Themba Nyrenda; Pritish Bhattacharyya; Michael B Harris; Andre Goy; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-10-11